1 February 2017
By Helen Kimberley
With the UK Government firmly indicating a "Hard Brexit", regulatory cooperation between the UK and EU is set to be key for a number of industries post-Brexit. Jeremy Hunt, the Secretary of State for Health, has recognised that while he does not expect the UK to remain part of the EU medicines regulatory framework (read more here), he expects the UK to continue to work closely with the European Medicines Agency (EMA) and potential mutual recognition between the MHRA (The Medicines and Healthcare products Regulatory Agency in the UK) and the EMA. Arguably, and as Mr Hunt emphasised, this is something that would benefit both the UK and the EU and will be encouraging for the UK life sciences industry.
Industries: Life Sciences and Healthcare
Jurisdictions: United Kingdom